This article is more than 5 years old. Information may no longer be current.
AHA late-breaking clinical trials announced
Click Here to Manage Email Alerts
New data from the CANTOS, COMPASS, FOURIER and REVEAL trials are among the late-breaking clinical trials selected for presentation at the American Heart Association Scientific Sessions from Nov. 11 to 15 in Anaheim, California.
According to a release by the AHA, the late-breakers will include an analysis of residual inflammatory risk and residual cholesterol risk from the CANTOS trial of canakinumab (ACZ885, Novartis), an economic analysis of rivaroxaban (Xarelto, Janssen) plus aspirin vs. aspirin alone in patients with atherosclerotic vascular disease from COMPASS, subgroup analyses of patients with peripheral artery disease and patients with MI from the FOURIER outcomes trial of evolocumab (Repatha, Amgen) and data on patients with diabetes included in the REVEAL trial of anacetrapib (Merck).
Three late-breakers concern patients undergoing cardiac surgery: TRICS III, which concerns transfusion triggers; DACAB, which compares ticagrelor (Brilinta, AstraZeneca) alone vs. ticagrelor plus aspirin after CABG; and BRUISE CONTROL-2, examining continued vs. interrupted use of direct oral anticoagulants in patients undergoing surgery.
Patients with diabetes are included in several late-breaking studies, including findings on primary and secondary prevention of CV events with canagliflozin (Invokana, Janssen) from the CANVAS program, the effect of exenatide (Byetta, Amylin/AstraZeneca) on patients with diabetes and CVD in the EXSCEL study, and a subanalysis of patients with PAD from the EMPA-REG Outcome study of empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly).
Quality improvement and patient-centered care are the focus of several late-breakers, including STIC2IT, a trial of a telepharmacy intervention to improve treatment adherence, and DECIDE-LVAD, which analyzes a shared decision-making intervention for patients with advanced HF offered a destination-therapy left ventricular assist device.
Several late-breakers focus on cell therapies, including PROPEL, a trial of granulocyte-macrophage colony-stimulating factor for patients with PAD; ALLSTAR, a study of allogenic heart stem cells to achieve myocardial regeneration; and HOPE-Duchenne, which evaluated cardiosphere-derived cells as a treatment for Duchenne cardiomyopathy.
Cardiology Today, Cardiology Today’s Intervention and Healio.com/Cardiology will be reporting live from the meeting. Stay tuned for news, videos, perspectives and more.